Cargando…

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

We characterized virus-neutralization and spike-binding antibody profiles in myeloma patients following monovalent or bivalent-SARS-CoV-2 booster vaccination. Vaccination improves the breadth of binding antibodies but not neutralization activity against current variants. Hybrid immunity and immune i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreno, Alberto, Manning, Kelly, Azeem, Maryam I., Nooka, Ajay K., Ellis, Madison, Manalo, Renee Julia, Switchenko, Jeffrey M., Wali, Bushra, Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Lonial, Sagar, Dhodapkar, Kavita M., Dhodapkar, Madhav V., Suthar, Mehul S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543400/ https://www.ncbi.nlm.nih.gov/pubmed/37790523 http://dx.doi.org/10.21203/rs.3.rs-3293339/v1

Ejemplares similares

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
por: Nooka, Ajay K., et al.
Publicado: (2022)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
por: Maples, Kathryn T., et al.
Publicado: (2023)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
por: Robinson, M. Hope, et al.
Publicado: (2023)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
por: McCachren, Samuel S., et al.
Publicado: (2021)

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
por: Dhodapkar, Madhav V., et al.
Publicado: (2019)

Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
por: Dhodapkar, Kavita M., et al.
Publicado: (2002)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
por: Costa, Federica, et al.
Publicado: (2018)

Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022)

Enhancement of clonogenicity of human multiple myeloma by dendritic cells
por: Kukreja, Anjli, et al.
Publicado: (2006)

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
por: Dhodapkar, Kavita M, et al.
Publicado: (2013)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
por: Chang, Andres, et al.
Publicado: (2022)

A survey-wide association study to identify youth-specific correlates of major depressive episodes
por: Dhodapkar, Rahul Madhav
Publicado: (2020)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis
por: Dhodapkar, Kavita, et al.
Publicado: (2015)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade
por: Dhodapkar, Kavita M.
Publicado: (2018)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
por: Chang, Andres, et al.
Publicado: (2023)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
por: Dhodapkar, Madhav V., et al.
Publicado: (2001)

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
por: Paiardini, Mirko, et al.
Publicado: (2020)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_67gtnpju5anld2oqsiv0tpfbf7